News

The primary end point of overall survival improvement has been reached in the phase 3 LUNAR study, which is evaluating Tumor Treating Fields in combination with standard therapies for the treatment of stage IV non–small cell lung cancer.

A phase 1/2 study of uproleselan combined with chemotherapy led to a complete response of 35% and median overall survival of 8.8 months in a cohort of patients with relapsed/refractory acute myeloid leukemia.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Board-certified hematologist and medical oncologist William T. McGarry, MD has joined the statewide practice.

INTRIGUE study results show that patients with gastrointestinal stromal tumor who harbor certain KIT mutations have significantly improved responses and survival with ripretinib treatment.

Andreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.

Based on findings from a phase 1 study, the FDA has received a biologics license application for cosibelimab for patients with advanced or metastatic cutaneous squamous cell carcinoma.

The THUNDER case-control study elicited a 69.1% rate of sensitivity and 98.9% rate of specificity with the OverC™ MCDBT in adult patients with various cancers.

The combination of PDS0101, M9241, and bintrafusp alfa elicited a promising median overall survival in patients with checkpoint inhibitor refractory advanced human papillomavirus-positive cancers.

Karen L. Reckamp, MD, discusses the current limitations with standard of care treatment for patients with non–small cell lung cancer.

A prospective, blinded study confirmed the accuracy of the detecting brain tumors with the TriNetraTM-Glio test, addressing an unmet medical need for experts in this space.

In an interview with Targeted Oncology, Jeffrey R. Schriber, MD, discussed the impact of new advancements in the treatment of multiple myeloma, like the use of BiTE cells, on the current and future landscape for this patient population.

In December 2022, the FDA granted 5 approvals, 2 breakthrough therapy designations, 1 fast track designation, lifted a clinical hold, cleared an investigational new drug application, and more.

Circulating tumor DNA has improved risk stratification, increased minimal residual disease in patients with early-stage gastrointestinal cancers.

When providing telehealth, providers must check individual state laws and policies regarding telehealth and providing telehealth across state lines. In sum, there is a lot to stay on top of in relation to telehealth.

Select racial groups have benefitted from important updates made to the USPSTF lung cancer screening guideline a year ago.

The CSP-targeting antibody, ZB131, is being investigated in a phase 1/2 study of patients with pancreatic cancer and other solid tumors.

According to a prospective study of lung cancer screening examinations conducted over a 5-year period, there is low adherence to guidelines recommending follow-up radiologic imaging or diagnostic procedures in patient with lung cancer.

In an interview with Targeted Oncology, Justin Taylor, MD, discussed the recent changes that have been seen with this new classification of MDS and how this review article can help make people more aware of the treatment options available.

Marc S. Ernstoff, MD, discusses metastatic melanoma and how patients may be managed.

The FDA has not made a decision on the approval application for toripalimab plus chemotherapy or toripalimab monotherapy for the treatment of advanced recurrent or metastatic nasopharyngeal carcinoma.

In an interview with Targeted Oncology, Jimmy Caudell, MD, PhD, discussed the biggest challenges being faced in the head and neck cancer space.

Michael Chuong, MD, discusses the study design of a trial evaluating radiation therapy in patients with locally advanced pancreatic cancer.

The Association of Community Cancer Centers is announcing the release of a new tool intended to facilitate education and adoption of new clinical and technological advancements in diagnosis, staging, and treatment of cancer.

The Association of Community Cancer Centers (ACCC) is grateful that Congress is poised to address many of our year-end policy priorities in its proposed fiscal year 2023 omnibus appropriations package released this week

Allan Pickens, MD, discusses the current treatment landscape for esophageal cancer.

In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.

In an interview with Targeted Oncology, Marc S. Ernstoff, MD, discusses recent updates in the management of metastatic melanoma.

In an interview with Targeted Oncology, Allan Pickens, MD, discussed research on racial disparities in surgery for esophageal cancer.

New published findings from the phase 1/2 KRYSTAL-1 study have caught the attention for the FDA.

In an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.